ORION PHARMA AND PHARMACIA ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE A NEW ANXIETY MEDICATION
| Source: Orion Oyj
Under the terms of the agreement, Orion Pharma and Pharmacia will conduct the Phase 3 clinical studies of deramciclane in the U.S. The clinical development program will be funded by Orion Pharma and planned and supervised jointly by the two companies. Pharmacia's clinical development organization will manage the Phase 3 trials.
Pharmacia will distribute and market deramciclane in the U.S. upon regulatory approval of the product. Orion Pharma will have an option to co-promote the product in the U.S. The agreement further provides Pharmacia with the rights to develop and market deramciclane in countries outside the U.S. and Europe including Japan.
The European studies and registrations are the sole responsibility of Orion Pharma and are not in the scope of the agreement between .....................................
Recommended Reading
-
ORION CORPORATION INTERIM REPORT 1–9/2026 28 OCTOBER 2026 at 12:00 EET Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D...
Read More -
ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET Changes in Orion Group’s Executive Team as of 1 January 2027 To accelerate the...
Read More